朗迪Reneed品牌怎么样 申请店铺

我要投票 朗迪Reneed在补钙行业中的票数:488 更新时间:2025-07-07
朗迪Reneed是哪个国家的品牌?「朗迪Reneed」是 北京振东康远制药有限公司 旗下著名品牌。该品牌发源于北京市,由创始人李昆在2003-11-07期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力朗迪Reneed品牌出海!将品牌入驻外推网,定制朗迪Reneed品牌推广信息,可以显著提高朗迪Reneed产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

朗迪Reneed怎么样

钙营养补充剂品牌,主打维生素矿物质钙补充剂类药物,集研发、生产、销售于一体的集团化现代综合制药企业


北京振东康远制药有限公司始建于2003年10月,是国内较大的具有自主品牌的维生素矿物质钙补充剂类药物生产企业,是一家集研发、生产、销售于一体的集团化现代综合制药公司,是中国补钙药物的佼佼者和先锋。公司产品遍布全国,公司“朗迪”牌碳酸钙D3片(II)和碳酸钙D3颗粒已成为中国钙补充剂类药品市场的主流。公司2015年与上市公司振东集团山西振东制药股份有限公司强强联合,完成重大重组,实现了跨跃式发展。

公司于2009年进入中国钙制剂市场,旗下现有7家直属或控股的制药公司、2家直属药物研发公司及多家医药贸易公司,在30多个城市设立了办事机构,有数千家合作伙伴,累计总投资超过10亿元,全国有数千名员工为康远工作。

公司位于北京市昌平区西部约15公里的北京市昌平区流村工业园内,隶属中关村科技园昌平园。该厂区自2012年开始建造,总投资近亿元,按照新版欧盟GMP标准及中国GMP标准进行规划、设计和建设施工,配有国际前沿的制粒、干燥、混合、压片、包装等片剂、硬胶囊剂、颗粒剂生产线及软胶囊剂生产线,该项目已于2014年通过了BFDA组织的GMP认证,并获得片剂、硬胶囊剂、颗粒剂、软胶囊剂GMP证书。项目年生产能力近百亿片(粒、袋)。该项目的建成使康远制药一跃成为国内维生素矿物质钙补充剂类药物较大生产企业。

公司发展过程中始终以“构建国人健康骨骼”为已任,以“树民族工业品牌,为中国制药争光”为使命,为中国钙制剂的发展做出了较大的贡献,大大改善了亿万国人的生活质量。康远人负有共同的使命,遵循一致的价值观,始终秉承“济世安康、立勋鸿远”宗旨来服务社会、回报社会。目前公司年营业收入达数十亿元,年上缴税金数亿元。随着公司高速发展和对未来中国经济和全球钙制剂市场发展前景充分信心,北京振东康远制药正不断加快创新、运筹帷幄、酝酿百年规划,未来的康远终将成为一家拥有精良技术和设备、管理成熟的世界制药公司。


Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd., a brand of calcium supplements, is a group modern comprehensive pharmaceutical enterprise integrating R & D, production and sales. It was founded in October 2003. It is a large domestic manufacturer of vitamin and mineral calcium supplements with its own brand, integrating R & D, production and sales Group modern comprehensive pharmaceutical company is the leader and pioneer of calcium supplements in China. The company's products are all over the country, and its "landi" brand calcium carbonate D3 tablets (II) and calcium carbonate D3 particles have become the mainstream of China's calcium supplements market. In 2015, the company and the listed company Zhendong Group Shanxi Zhendong Pharmaceutical Co., Ltd. jointly completed major restructuring and achieved a leap forward development. In 2009, the company entered the calcium preparation market in China. At present, it has 7 pharmaceutical companies directly under or controlled by the company, 2 pharmaceutical research and development companies directly under the company and many pharmaceutical trading companies. It has set up offices in more than 30 cities, thousands of partners, with a total investment of more than 1 billion yuan, and thousands of employees working for Kangyuan. The company is located in Liucun Industrial Park, Changping District, Beijing, about 15km away from the west of Changping District, Beijing. The plant has been constructed since 2012, with a total investment of nearly 100 million yuan. It is planned, designed and constructed in accordance with the new version of EU GMP standard and China GMP standard. It is equipped with internationally cutting-edge tablet, hard capsule, granule production line and soft capsule production line. The project has passed the GMP certification organized by bfda in 2014, and has obtained tablet GMP certificate of hard capsule, granule and soft capsule. The annual production capacity of the project is nearly 10 billion pieces (grain and bag). With the completion of the project, Kangyuan pharmaceutical has become a large domestic manufacturer of vitamin, mineral and calcium supplements. In the development process of the company, we always take "building healthy skeleton of Chinese people" as our responsibility, take "building national industrial brand, winning honor for Chinese pharmaceutical" as our mission, and have made great contribution to the development of Chinese calcium preparation, greatly improving the quality of life of hundreds of millions of Chinese people. Kangyuan people have a common mission, follow the same values, and always adhere to the tenet of "helping the world and health, and making contributions to Hongyuan" to serve and repay the society. At present, the company's annual operating revenue is billions of yuan, and the annual tax payment is hundreds of millions of yuan. With the rapid development of the company and full confidence in the future development of China's economy and the global calcium preparation market, Beijing Zhendong Kangyuan Pharmaceutical Co., Ltd. is constantly accelerating innovation, strategizing and brewing a hundred year plan. In the future, Kangyuan will eventually become a world pharmaceutical company with excellent technology and equipment and well managed.

本文链接: https://brand.waitui.com/52bc17e3b.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

欧盟推迟与中国签署气候行动联合声明,外交部回应

7月7日,外交部发言人毛宁主持例行记者会。路透社记者提问,英国《金融时报》报道,欧盟推迟了本月与中国签署气候行动联合声明的计划。报道称,欧盟表示,除非中国承诺加大力度削减温室气体排放,否则欧盟不会希望这份联合声明提前签署。中欧将在本月举行峰会,中国是否也在考虑做出更多气候承诺?毛宁表示,具体的问题建议你向中方的主管部门询问。我可以告诉你的是,中国始终积极推进绿色低碳发展。过去10年,中国的非化石能源占能源消费总量的比重增加至17.9%,碳排放强度下降了超过34%。我们将继续同各国一道加强应对气候变化的国际合作,为绿色转型和人类的可持续发展作出贡献。(澎湃)

34分钟前

机构:今年以来全球新船订单总量同比下降54%

据克拉克森研究统计,年初至今全球新船订单总量同比下降54%。克拉克森新造船价格指数同比下滑1%。集装箱船(新船订单量达到190万标准箱)、邮轮和渡轮新造船市场依然保持活跃;而气体船和油轮新造船投资放缓。新船交付保持稳定,中国船厂占比达到48%、韩国占31%、日本占13%;不过中国船厂新船订单份额有所下滑,从2024年的70%降至52%。(证券时报)

34分钟前

中国动力:预计上半年净利润同比增长68.28%到141.90%

36氪获悉,中国动力公告,预计2025年半年度实现归属于母公司所有者的净利润80000万元到115000万元,同比增加68.28%到141.90%。业绩预增的主要原因是船舶行业增长,公司柴油机板块销售规模扩大,合同结算增加,产品价格增长以及毛利率提升。

34分钟前

皖维高新:上半年净利润同比预增81.34%—104.48%

36氪获悉,皖维高新公告,预计2025年半年度公司实现净利润为2.35亿元—2.65亿元,同比增长81.34%—104.48%。报告期内,行业下游市场逐步回暖,客户需求有所提升,公司主产品聚乙烯醇(PVA)、醋酸乙烯、醋酸甲酯的销量同比增长。其中,PVA实现了销量和价格的双增长。

34分钟前

印尼首席谈判代表将于周一访问美国,以赶在关税截止日期前完成谈判

印尼经济事务协调部发言人哈里奥·利曼塞托表示,该国在美关税谈判的主要代表、高级经济部长阿里朗加·哈拉托计划于周一前往美国。阿里朗加目前正陪同总统普拉博沃·苏比安托参加金砖国家会议,之后他将前往美国监督关税谈判,以确保在 7 月 9 日的截止日期前完成谈判,该日期已临近。(新浪财经)

34分钟前

本页详细列出关于朗迪Reneed的品牌信息,含品牌所属公司介绍,朗迪Reneed所处行业的品牌地位及优势。
咨询